Tacrolimus Pharmacokinetics is Associated with Gut Microbiota Diversity in Kidney Transplant Patients: Results from a Pilot Cross‐Sectional Study

• Published in: Clinical pharmacology and therapeutics Vol. 115; no. 1; pp. 104 - 115
• Main Authors: Degraeve, Alexandra L., Bindels, Laure B., Haufroid, Vincent, Moudio, Serge, Boland, Lidvine, Delongie, Kevin‐Alexandre, Dewulf, Joseph P., Eddour, Djamila Chaib, Mourad, Michel, Elens, Laure
• Format: Journal Article
• Language: English
• Published: United States 01.01.2024
• Subjects: Cross-Sectional Studies; Cytochrome P-450 CYP3A - genetics; Gastrointestinal Microbiome - genetics; Genotype; Humans; Immunosuppressive Agents - adverse effects; Immunosuppressive Agents - pharmacokinetics; Kidney Transplantation - adverse effects; Pilot Projects; RNA, Ribosomal, 16S - genetics; Tacrolimus - pharmacokinetics
• DOI: 10.1002/cpt.3077
• ISSN: 0009-9236

Clinical use of tacrolimus (TAC), an essential immunosuppressant following transplantation, is complexified by its high pharmacokinetic (PK) variability. The gut microbiota gains growing interest but limited investigations have evaluated its contribution to TAC PKs. Here, we explore the associations between the gut microbiota composition and TAC PKs. In this pilot cross‐sectional study (Clinicaltrial.gov NCT04360031), we recruited 93 CYP3A5 non‐expressers stabilized kidney transplant recipients. Gut microbiota composition was characterized by 16S rRNA gene sequencing, TAC PK parameters were computed, and additional demographic and medical covariates were collected. Associations between PK parameters or diabetic status and the gut microbiota composition, as reflected by α‐ and β‐diversity metrics, were evaluated. Patients with higher TAC area under the curve AUC/(dose/kg) had higher bacterial richness, and TAC PK parameters were associated with specific bacterial taxa (e.g., Bilophila) and amplicon sequence variant (ASV; e.g., ASV 1508 and ASV 1982 (Veillonella/unclassified Sporomusaceae); ASV 664 (unclassified Oscillospiraceae)). Building a multiple linear regression model showed that ASV 1508 (co‐abundant with ASV 1982) and ASV 664 explained, respectively, 16.0% and 4.6% of the interindividual variability in TAC AUC/(dose/kg) in CYP3A5 non‐expresser patients, when adjusting for hematocrit and age. Anaerostipes relative abundance was decreased in patients with diabetes. Altogether, this pilot study revealed unprecedented links between the gut microbiota composition and diversity and TAC PKs in stable kidney transplant recipients. It supports the relevance of studying the gut microbiota as an important contributor to TAC PK variability. Elucidating the causal relationship will offer new perspectives to predict TAC inter‐ and intra‐PK variability.